GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Alk-Abello A/S (STU:4AJ0) » Definitions » Cyclically Adjusted PB Ratio

Alk-Abello A/S (STU:4AJ0) Cyclically Adjusted PB Ratio : 7.25 (As of Jun. 19, 2024)


View and export this data going back to 2014. Start your Free Trial

What is Alk-Abello A/S Cyclically Adjusted PB Ratio?

As of today (2024-06-19), Alk-Abello A/S's current share price is €18.93. Alk-Abello A/S's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was €2.61. Alk-Abello A/S's Cyclically Adjusted PB Ratio for today is 7.25.

The historical rank and industry rank for Alk-Abello A/S's Cyclically Adjusted PB Ratio or its related term are showing as below:

STU:4AJ0' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.65   Med: 6.56   Max: 12.11
Current: 8.5

During the past years, Alk-Abello A/S's highest Cyclically Adjusted PB Ratio was 12.11. The lowest was 2.65. And the median was 6.56.

STU:4AJ0's Cyclically Adjusted PB Ratio is ranked worse than
87.54% of 658 companies
in the Biotechnology industry
Industry Median: 1.665 vs STU:4AJ0: 8.50

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Alk-Abello A/S's adjusted book value per share data for the three months ended in Mar. 2024 was €2.842. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €2.61 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


Alk-Abello A/S Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Alk-Abello A/S's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alk-Abello A/S Cyclically Adjusted PB Ratio Chart

Alk-Abello A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.24 9.24 11.99 6.01 6.06

Alk-Abello A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.51 4.56 4.78 6.06 7.24

Competitive Comparison of Alk-Abello A/S's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Alk-Abello A/S's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Alk-Abello A/S's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Alk-Abello A/S's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Alk-Abello A/S's Cyclically Adjusted PB Ratio falls into.



Alk-Abello A/S Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Alk-Abello A/S's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=18.93/2.61
=7.25

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alk-Abello A/S's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, Alk-Abello A/S's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=2.842/118.4000*118.4000
=2.842

Current CPI (Mar. 2024) = 118.4000.

Alk-Abello A/S Quarterly Data

Book Value per Share CPI Adj_Book
201406 1.522 99.700 1.807
201409 1.631 99.700 1.937
201412 1.637 99.400 1.950
201503 1.696 100.200 2.004
201506 1.721 100.300 2.032
201509 1.753 100.200 2.071
201512 1.849 99.800 2.194
201603 1.895 100.200 2.239
201606 1.943 100.600 2.287
201609 1.937 100.200 2.289
201612 1.965 100.300 2.320
201703 1.930 101.200 2.258
201706 1.905 101.200 2.229
201709 1.881 101.800 2.188
201712 2.054 101.300 2.401
201803 2.050 101.700 2.387
201806 2.042 102.300 2.363
201809 2.016 102.400 2.331
201812 1.975 102.100 2.290
201903 2.030 102.900 2.336
201906 1.952 102.900 2.246
201909 1.964 102.900 2.260
201912 1.950 102.900 2.244
202003 2.009 103.300 2.303
202006 1.992 103.200 2.285
202009 1.972 103.500 2.256
202012 1.939 103.400 2.220
202103 2.035 104.300 2.310
202106 1.990 105.000 2.244
202109 2.030 105.800 2.272
202112 2.129 106.600 2.365
202203 2.232 109.900 2.405
202206 2.310 113.600 2.408
202209 2.401 116.400 2.442
202212 2.426 115.900 2.478
202303 2.503 117.300 2.526
202306 2.541 116.400 2.585
202309 2.632 117.400 2.654
202312 2.697 116.700 2.736
202403 2.842 118.400 2.842

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Alk-Abello A/S  (STU:4AJ0) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Alk-Abello A/S Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Alk-Abello A/S's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Alk-Abello A/S (STU:4AJ0) Business Description

Industry
Address
Boge Alle 6-8, Horsholm, DNK, DK-2970
Alk-Abello A/S is a biotechnology company that focuses on pharmaceutical prevention, diagnosis, and treatment of allergies. The company is focused on respiratory diseases, including allergic rhinitis and allergic asthma. Moreover, the firm specializes in venom immunotherapy for patients suffering from bee and wasp allergies. The company's treatments induce a protective immune response that provides sustained symptom relief. Its primary focus is on allergy patients whose disease is not well controlled, despite the use of symptom-relieving medication.

Alk-Abello A/S (STU:4AJ0) Headlines

No Headlines